by Stephen Levin
It is not at all uncommon for a medical device start-up company to begin by focusing on a particular clinical...
Stentys' Shifting Focus: Moving Beyond Bifurcations, Stenting for AMI
Launched to develop a better stent for treating bifurcated lesions, Stentys discovered its device appears to be effective in treating a larger unmet clinical need: acute myocardial infarction. This strategy shift holds great promise, but the company must convince physicians that its self-expanding stent will succeed where others have failed, and that it is superior to traditional stents from the major cardiovascular players.
More from Archive
More from In Vivo
• By
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
• By
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
• By
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.